No Evidence FDA Sabotaged $375K-A-Year Drug, Judge Says
The U.S. Food and Drug Administration lawfully approved a lower-cost version of a $375,000-per-year drug for a rare autoimmune disease because the agency reasonably interpreted the Orphan Drug Act where it fell short,...To view the full article, register now.
Already a subscriber? Click here to view full article